TRASTUZUMAB AND PERTUZUMAB COMBINATION THERAPY ACTIVATES COMPLEMENT-DEPENDENT CYTOTOXICITY AND PHAGOCYTOSIS AGAINST HER2+BREAST CANCER

被引：0
|
作者：
Tsao, Li-Chung [1 ]
Hartman, Zachary [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617
引用
收藏
页码：A647 / A647
页数：1
相关论文
共 50 条
  • [1] Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis
    Tsao, Li-Chung
    Crosby, Erika J.
    Trotter, Timothy N.
    Wei, Junping
    Wang, Tao
    Yang, Xiao
    Summers, Amanda N.
    Lei, Gangjun
    Rabiola, Christopher A.
    Chodosh, Lewis A.
    Muller, William J.
    Lyerly, Herbert Kim
    Hartman, Zachary C.
    JCI INSIGHT, 2022, 7 (06)
  • [2] Pruritus related to trastuzumab and pertuzumab in HER2+breast cancer patients
    Gu, Stephanie
    Dusza, Stephen
    Quigley, Elizabeth
    Haliasos, Helen
    Markova, Alina
    Marchetti, Michael
    Moy, Andrea P.
    Dang, Chau
    Modi, Shanu
    Lake, Diana
    Noor, Sarah
    Lacouture, Mario E.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 271 - 280
  • [3] HOSPITAL CAPACITY TOOL TO ASSESS THE POTENTIAL IMPACT OF USING A FIXED DOSE COMBINATION OF PERTUZUMAB/TRASTUZUMAB FOR SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS PERTUZUMAB/ TRASTUZUMAB IN HER2+BREAST CANCER
    Cunha, A.
    VALUE IN HEALTH, 2023, 26 (12) : S296 - S296
  • [4] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+Breast Cancer
    Franco-Mateos, Emma
    Souza-Egipsy, Virginia
    Garcia-Estevez, Laura
    Perez-Garcia, Jose
    Gion, Maria
    Garrigos, Laia
    Cortez, Patricia
    Saavedra, Cristina
    Gomez, Patricia
    Ortiz, Carolina
    Cruz, Victor L.
    Ramos, Javier
    Cortes, Javier
    Vega, Juan F.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [6] Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
    Beitsch, Peter
    Whitworth, Pat
    Baron, Paul
    Rotkis, Michael C.
    Mislowsky, Angela M.
    Richards, Paul D.
    Murray, Mary K.
    Pellicane, James V.
    Dul, Carrie L.
    Nash, Charles H.
    Stork-Sloots, Lisette
    de Snoo, Femke
    Untch, Sarah
    Lee, Laura A.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (09) : 2539 - 2546
  • [7] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [8] COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [9] Acquired resistance to trastuzumab and neratinib sensitizes HER2+breast cancer cells to trastuzumab-dependent cell-mediated cytotoxicity
    Ramirez, Javier Sanchez
    O'Reilly, Debbie
    Crown, John
    Collins, Denis M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1089 - 1089
  • [10] Investigating trastuzumab-induced myeloid cell alterations for improving combination therapy in HER2+breast cancer
    Bloom, M. J.
    Jarrett, A. M.
    Triplett, T. A.
    Syed, A. K.
    Yankeelov, T. E.
    Sorace, A. G.
    CANCER RESEARCH, 2019, 79 (04)
12345